CTA
PBYI icon

Carillon Tower Advisers’s Puma Biotechnology PBYI Stock Holding History

Carillon Tower Advisers’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-207,820
Closed -$12.3M – 463
2018
Q2 		$12.3M Hold
207,820
– – 0.1% 298
2018
Q1 		$13.4M Hold
207,820
– – 0.1% 261
2017
Q4 		$20.5M Buy
+207,820
New +$23.3M 0.22% 176

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Carillon Tower Advisers's PBYI Position: Q3 2018 in Review

Carillon Tower Advisers sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 207,820 shares — an estimated $12.3M sold.

Carillon Tower Advisers first reported a position in PBYI in Q4 2017 and held it in 3 quarters. The position peaked at $20.5M in Q4 2017. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

  • Carillon Tower Advisers reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
  • Carillon Tower Advisers sold 207,820 Puma Biotechnology shares in Q3 2018, an estimated $12.3M.
  • Carillon Tower Advisers first reported a position in Puma Biotechnology in Q4 2017 and held it in 3 quarters.
  • Carillon Tower Advisers's Puma Biotechnology position peaked at $20.5M in Q4 2017.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Carillon Tower Advisers's 13F filing for Q3 2018, filed 13 Nov 2018.